DXCM earnings analysis
What we found in DXCM's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
DexCom, Inc. (DXCM) posted strong Q1 2026 results, with revenue reaching $1.192 billion, up 15% year-over-year, exceeding estimates of $1.176 billion. EPS improved significantly to $0.51 from $0.27 in the prior year. Operating cash flows were robust at $525.6 million, reflecting increased customer adoption and operational efficiencies, despite ongoing challenges such as pricing headwinds and competition.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Strong Revenue Growth
- Q1 2026 revenue was $1.192 billion, a 15% increase from $1.036 billion in Q1 2025.
- Improved EPS Performance
- Diluted EPS rose to $0.51 from $0.27 in Q1 2025, marking a 89% increase.
- Record Operating Income
- Operating income surged to $255.3 million from $133.7 million, a 91% year-over-year increase.
- Cash Flow Growth
- Operating cash flow was $525.6 million, up 186% compared to $183.8 million in Q1 2025.
- Increased Gross Margin
- Gross profit margin improved to 62.9%, up from 56.9% in Q1 2025.
- Solid Cash Reserves
- Cash and equivalents plus short-term investments totaled $2.42 billion at March 31, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Litigation Risks
- Ongoing securities class actions and derivative lawsuits could impose significant costs and damages.
- Foreign Exchange Exposure
- Expansion into international markets exposes DXCM to currency fluctuations affecting financial results.
- Market Competition
- Increased competition in the diabetes management industry may impact market share and pricing.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.51
- Gross margin
- 62.9%
- Operating margin
- 21.4%
What they said about what is next.
Revenue guidance maintained at $5.16 to $5.25 billion for FY 2026, with anticipated improved margins.
The filing reads better than the one before it.
What came before.
- 10-K · February 12, 2026
- DexCom’s 10-K emphasizes a product-led strategy: roll out the G7 family (including the April 2025 FDA-cleared G7 15 Day) and expand access via Stelo (OTC, launched August 2024) while leveraging integrations with insulin…
- 10-Q · October 30, 2025
- DexCom reported strong Q3 results with revenue of $1,209.3 million, up $215.1 million (21.6%) versus Q3 2024, and net income of $283.8 million driving diluted EPS to $0.70 from $0.34 a year ago. Gross profit expanded to…
- 10-Q · May 1, 2025
- DexCom reported revenue of $1,036.0 million for the quarter ended March 31, 2025, up $115.0 million (12.5%) versus the three months ended March 31, 2024. Gross margin compressed to 56.9% while operating income improved…
- 10-K · February 18, 2025
- DexCom’s 10-K emphasizes product-led growth (G7 and the August 2024 OTC Stelo launch), ecosystem partnerships (insulin delivery integrations and a Verily collaboration), and a recurring-sensor revenue model. The filing…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing DXCM makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever